Addex Therapeutics completes recruitment of patients in ADX71149

Addex Therapeutics (ADXN) announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. The trial is being conducted in collaboration with Janssen Pharmaceuticals, a Johnson & Johnson (JNJ) company. As previously announced on May 10, an independent Interim Review Committee, or IRC, convened by Janssen recommended to continue the study following review of unblinded data from Part 1 of patient Cohort 1.